sun pharma semaglutide Gets Nod for Generic Amid Market Boom Eris Lifesciences and Sun Pharma

[27] Sobre el cerebro enfermo, el tratamiento con agonistas del receptor GLP-1 se asocia con proteccin contra una variedad de modelos experimentales de enfermedades como la enfermedad de Parkinson, [28] [22] la enfermedad de Alzheimer, [29] [30] el accidente cerebrovascular, [28] la lesin cerebral traumtica, [31] [23] y la esclerosis mltiple

Briefly, embryos were surgically removed and the cortical areas were dissected from the cerebral tissue in Hanks balanced salt solution (HBSS, Gibco, Life Technologies, cat.# 14170088), freed of meninges, digested with 0.25% trypsin (Gibco, Life Technologies, cat.# 15090-046) for 15 min at 37C, dissociated by trituration and plated (10 6 cells/dish) on 35 mm poly-L-lysine-coated wells (Poly-Lysine hydrobromide, Sigma-Aldrich, cat.# P5899) in Earles minimum essential medium (MEM, Gibco, Life Technologies, ca.#t 41090-028) containing 10% foetal bovine serum (Gibco, Life Technologies, cat.# 16000-044) and 2% glucose (Sigma-Aldrich, cat.# G7021)

The approval positions the pill as a potential alternative to injectable GLP-1 therapies and is expected to become available in the US in early January 2026

The findings demonstrated that intermittent fasting significantly reduced body weight